Soleno Therapeutics (SLNO) Common Equity (2013 - 2026)
Soleno Therapeutics (SLNO) posted quarterly Common Equity of $495.8 million for Q1 2026, up 113.47% year-over-year from $232.3 million in Q1 2025, and up 10.15% quarter-over-quarter from $450.1 million in Q4 2025.
Soleno Therapeutics (SLNO) Common Equity (2013 - 2026) Analysis & Trends
Soleno Therapeutics (SLNO) has reported Common Equity for 14 consecutive years, with $495.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity rose 113.47% year-over-year to $495.8 million; the TTM figure through Mar 2026 stood at $495.8 million (up 113.47% YoY), while the FY2025 annual figure was $450.1 million, up 83.64% from the prior year.
- Common Equity grew to $495.8 million in Q1 2026 per SLNO's latest filing, from $450.1 million in the prior quarter.
- Across five years, Common Equity topped out at $495.8 million in Q1 2026 and bottomed at $2.6 million in Q1 2023.
- Historically, Common Equity has averaged $183.2 million across 5 years, with a median of $157.5 million in 2023.
- Annual changes were most pronounced in 2023 — Common Equity tumbled 90.03% — and 2024, when it jumped 5333.35%.
- Soleno Therapeutics' Common Equity stood at $10.3 million in 2022, then soared by 1422.1% to $157.5 million in 2023, then surged by 55.62% to $245.1 million in 2024, then surged by 83.64% to $450.1 million in 2025, then gained by 10.15% to $495.8 million in 2026.
- Business Quant data shows SLNO's Common Equity at $495.8 million in Q1 2026, $450.1 million in Q4 2025, and $494.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Soleno Therapeutics | 2.74 Bn | 2.49 Bn | 93.41 Mn | 495.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 495.80 Mn |
| Dec 31, 2025 | 450.12 Mn |
| Sep 30, 2025 | 494.81 Mn |
| Jun 30, 2025 | 240.14 Mn |
| Mar 31, 2025 | 232.26 Mn |
| Dec 31, 2024 | 245.11 Mn |
| Sep 30, 2024 | 264.70 Mn |
| Jun 30, 2024 | 280.76 Mn |
| Mar 31, 2024 | 143.39 Mn |
| Dec 31, 2023 | 157.51 Mn |
| Sep 30, 2023 | 23.22 Mn |
| Jun 30, 2023 | 12.43 Mn |
| Mar 31, 2023 | 2.64 Mn |
| Dec 31, 2022 | 10.35 Mn |
| Sep 30, 2022 | 15.20 Mn |
| Jun 30, 2022 | 20.31 Mn |
| Mar 31, 2022 | 26.46 Mn |
| Dec 31, 2021 | 17.79 Mn |
| Sep 30, 2021 | 20.20 Mn |
| Jun 30, 2021 | 27.44 Mn |